Rifampicin alone
Phase 3Small molecule
Rifampicin alone is one of 49 small molecule programs targeting Kidney Disease. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
105 competitors in Kidney Disease
#DrugCompanyPhaseTrials
1Myrbetriq
AstellasApproved
Norvir
AbbVieApproved
Tafinlar
NovartisApproved
Xtandi
AstellasApproved
Medrol
PfizerApproved
Afinitor
NovartisApproved
Maxipime
PfizerApproved
Kisqali
NovartisApproved
Nexavar
BayerApproved
Zyloprim
Jazz PharmaceuticalsApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Rifampicin alone. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- MMiguel Santín